# US 2025/0368618 A1 · Benzoheterocyclic substituted tetrahydroisoquinoline compound salt form and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0368618 A1
- Document ID: US20250368618A1
- Status: Published application
- Kind: A1
- Application number: 18/876,938
- Filed: 2023-06-20
- Published: 2025-12-04
- Earliest claimed: 2022-06-20
- Assignees: Shanghai Jeyou Pharmaceutical Co., Ltd.
- Applicants: Shanghai Jeyou Pharmaceutical Co., Ltd.
- Inventors: Jin ZHANG; Jian HUANG
- Web page: https://patentgrep.com/patent/US20250368618A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07D 401/14: containing three or more hetero rings
- A61K 31/4725: containing further heterocyclic rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 13/12: of the kidneys
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A benzoheterocyclic substituted tetrahydroisoquinoline compound salt form and a preparation method therefor are provided. An amorphous form and salt form of the compound as shown in formula (I) can be used to inhibit NHE-mediated sodium ion or hydrogen ion reverse transfer.

## Claims

### Claim 1

An amorphous form, 1,5-naphthalenedisulfonate or hydrochloride of a compound represented by formula (I),
wherein the 1,5-naphthalenedisulfonate of the compound represented by formula (I) has a structure as shown below:
wherein
n=0.9-2.0; and
wherein the hydrochloride of the compound represented by formula (I) has a structure as shown below:
wherein
m=1.6-4.2.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

A method for preparing the 1,5-naphthalenedisulfonate of the compound represented by formula (I) as defined in claim 1, comprising a reaction as shown below,
wherein
n=0.9-2.0; and
a reaction solvent is selected from isopropanol, ethyl acetate, or a mixture of isopropanol and ethyl acetate.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the feeding molar ratio of the compound represented by formula (I) to 1,5-naphthalenedisulfonic acid is 1:(1-4);
optionally, the molar volume ratio of the compound represented by formula (I) to isopropanol is (5-15) mmol:(50-150) mL;
optionally, the molar volume ratio of the compound represented by formula (I) to ethyl acetate is (5-15) mmol:(50-150) mL;
optionally, the method further comprises a stirring treatment, a suction filtration treatment, and a drying treatment after the reaction is completed;
optionally, the stirring treatment is performed at room temperature for two days;
optionally, the suction filtration treatment is performed under nitrogen atmosphere;
optionally, the drying treatment is performed under a vacuum condition at room temperature for 2 h.

### Claim 5

(canceled)

### Claim 6

A method for preparing a compound represented by formula (III-1), comprising a reaction as shown below,
wherein
m1=1.6-2.5; and
a reaction solvent is selected from methyl tert-butyl ether.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the feeding molar ratio of the compound represented by formula (I) to ethyl acetate-hydrogen chloride is (2-10):(1-5);
optionally, the molar volume ratio of the compound represented by formula (I) to methyl tert-butyl ether is (5-15) mmol:(50-150) mL;
optionally, the method further comprises a stirring treatment, a suction filtration treatment, and a drying treatment after the reaction;
optionally, the stirring treatment is performed at room temperature for two days;
optionally, the suction filtration treatment is performed under nitrogen atmosphere;
optionally, the drying treatment is performed under a vacuum condition at room temperature for 2 h.

### Claim 8

A method for preparing a compound represented by formula (III-2), wherein
wherein
m2=3.8-4.2; and
a reaction solvent is methanol.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the reaction is performed under nitrogen atmosphere;
optionally, the feeding molar ratio of the compound represented by formula (I) to HCl/MeOH is (1-5):(2-10);
optionally, the molar volume ratio of the compound represented by formula (I) to methanol is (1-5) kg:(10-50) L;
optionally, a stirring treatment is performed for 30 min;
optionally, a slurring treatment is performed in ethyl acetate for 2 h.

### Claim 10 (depends on 1)

A method for treating a disease related to NHE-mediated antiport of a sodium ion or a hydrogen ion, comprising administering to a subject in need thereof a therapeutically effective amount of the amorphous form, the 1,5-naphthalenedisulfonate or the hydrochloride of the compound represented by formula (I) according to claim 1.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the disease related to NHE-mediated antiport of a sodium ion or a hydrogen ion is selected from irritable bowel syndrome, heart failure, chronic kidney disease, end-stage renal disease, and liver disease.
